Creative Planning
EDIT icon

Creative Planning’s Editas Medicine EDIT Stock Holding History

Creative Planning’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-500
Closed -$18K – 2629
2020
Q4 		$18K Hold
500
– – ﹤0.01% 2193
2020
Q3 		$2K Buy
+500
New +$16.3K ﹤0.01% 2091

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Creative Planning's EDIT Position: Q1 2026 in Review

Creative Planning opened a new position in Editas Medicine (EDIT) in Q1 2026: 23,084 shares worth $57K. The stake represents ﹤0.01% of the portfolio and ranks #3973 among its holdings. This is a return to the name: Creative Planning previously reported a position in EDIT as recently as Q3 2024.

Creative Planning first reported a position in EDIT in Q1 2016 and has held it in 26 quarters since. The position peaked at $1.5M in Q4 2019. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Creative Planning held 23,084 shares of Editas Medicine worth $57K as of Q1 2026.
  • Editas Medicine was a new Creative Planning position in Q1 2026.
  • Editas Medicine made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #3973 holding.
  • Creative Planning first reported a position in Editas Medicine in Q1 2016 and has held it in 26 quarters since.
  • Creative Planning's Editas Medicine position peaked at $1.5M in Q4 2019.
  • 207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.